A genetic variant carried by at least one-fifth of the population may do far more than raise the odds of developing Alzheimer ...

OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...

Add Yahoo as a preferred source to see more of our stories on Google. Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a rare ...

Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.

Scientists at Oregon Health & Science University's Casey Eye Institute and Baylor College of Medicine's Cullen Eye Institute published findings from a two-year Phase I clinical trial in the journal ...

The first study to evaluate both eyes treated with a gene therapy targeting neovascular, or wet, age-related macular degeneration (AMD) has found the treatment as safe and effective in the second eye ...

Key takeaways. Aging is not an inevitable process and can potentially be reversed. People may live into the twenty-second century with the right practices. Reversing aging could l ...

Preliminary results from the Phase 2 ArMaDa clinical trial indicate a 46% reduction in lesion growth compared to the control group after 12 months, with no serious adverse events reported across both ...

The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February 1, ...